Advaxis provides revise on survival details from ADXS11-001 phase 1 trial in cervix cancer Advaxis.

Advaxis provides revise on survival details from ADXS11-001 phase 1 trial in cervix cancer Advaxis, Inc., , the live, attenuated Listeria monocytogenes immunotherapy company, has up to date the survival details from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix tumor in females whose disease progressed after treatment with cytotoxic therapy. The main investigator for this research has reported that the two patients who were alive in March of 2010 remain alive at 3 contactez .9 and 3.5 years dosing post.

Through QualityEdge, providers can more collect and analyze data on the efficiency of their methods easily. ‘ AdvantEdge offers QualityEdge to select clients with general availability anticipated later this season now. In addition, AdvantEdge can be demonstrating QualityEdge at two upcoming conferences: ASA Annual Meeting: Anesthesiology 2013 at booth #2204 on Oct.12-16 in SAN FRANCISCO BAY AREA, and the ASA Quality Meeting: Creating and Measuring Quality in Anesthesiology at booth #3 on Nov. 9-10 in Rosemont, Ill.. AdvantEdge Healthcare launches QualityEdge information catch service AdvantEdge Healthcare Solutions, one of the nation's leading providers of medical billing, practice management, and coding services for specialty physicians, hospitals, and medical procedures centers, is launching its QualityEdgeSM details capture service, which allows physicians and other companies to easily capture data that would otherwise require paper notes or the use of an EMR.